Should You Really Buy Stocks With the S&P 500 Near Its Record High? Historical Data Gives a Clear Answer.

The S&P 500 has recovered to a new record high after briefly falling 9% below its peak on March 30, even as Middle East tensions and inflation have reaccelerated. Wall Street’s bottom-up forecast points to 8,326 over the next year, implying 17% upside from the current 7,110 level, while consensus earnings growth is nearly 20% in 2026. Valuation remains elevated at 21.1x forward earnings versus a 19.9x five-year average, so the article urges caution despite the bullish historical setup.

Analysis

The more important signal here is not that equities are at highs, but that the market is choosing to look through a macro shock while positioning remains underweight duration-sensitive inflation risk. That usually happens when investors believe the inflation impulse is transitory or offset by earnings breadth; the danger is that oil-driven inflation is regressive and hits consumer and small-cap margins before it shows up in headline index earnings. In other words, the index can levitate while internal dispersion widens, which tends to favor quality compounders and punitive for cyclicals with weak pricing power.

The consensus upside to the index is less actionable than the composition of that upside. If forward estimates are right, the winners are likely to be stocks with high operating leverage to AI capex, data/market infrastructure, and healthcare services, while the losers are names that depend on stable real incomes and benign input costs. That is constructive for NVDA and FDS on different vectors: NVDA because capex reacceleration is still intact, FDS because volatility and higher rates typically support terminal/workflow demand, but it is a headwind for businesses with consumer or transaction sensitivity if inflation persists into the next two prints.

The contrarian read is that record highs can be a false comfort when they are achieved on a narrow earnings story and policy repricing risk is rising. If gasoline keeps pressure on CPI into the next 4-8 weeks, the market may start to question the 2026 earnings ramp rather than the valuation multiple first; that sequence usually hurts high-multiple software/mega-cap momentum before it hurts the index itself. NDAQ is the cleanest hedge on the tape because higher volatility and turnover support structural trading activity, but it is also a better relative long than an outright index long if the market starts to price in more turbulence.

The market is missing that 'buying the highs' only works when macro shocks do not change the earnings dispersion regime. If inflation continues to reaccelerate, the biggest second-order effect may be a rotation from broad beta into index-adjacent infrastructure and defensives, not a simple market-wide correction. That argues for staying invested, but with tighter factor control and explicit hedges rather than buying SPX outright at current valuation.

Key Decisions for Investors

• Go long NVDA vs. short a basket of inflation-sensitive consumer cyclicals for 1-3 months; if earnings hold and AI capex remains intact, the pair should outperform on dispersion even if the index chops sideways.
• Add FDS on a 3-6 month horizon as a quality/volatility beneficiary; risk/reward improves if inflation stays sticky and client activity rises, but trim if real rates back up sharply and multiples compress.
• Initiate a tactical long NDAQ as a market-activity hedge into the next 4-8 weeks; higher volatility and elevated turnover can offset broad-market drawdown risk, with less exposure to margin-compression than pure beta.
• Use SPX or SPY put spreads 2-3 months out as portfolio insurance rather than de-risking core longs; the main risk is an inflation surprise that reprices rates before earnings estimates are revised.
• Avoid chasing the index at current levels; if you want beta exposure, scale in on a 5-7% pullback or after the next CPI print confirms inflation is not reaccelerating further.